1887

Abstract

Envelopes of retroviruses, including human immunodeficiency virus and simian immunodeficiency virus (SIV), contain host cell proteins that potentially represent novel targets for vaccine development. We show here that sera from rhesus macaques recognized simian major histocompatibility complex (MHC) molecules in response to infection with SIV. Antibodies from these animals did not cross-react with human MHC antigens on mitogen-activated peripheral blood mononuclear cells. The development of antibodies to MHC class I -chain did not correlate with anti-SIV envelope antibody responses, suggesting that these antibodies did not arise through molecular mimicry. In contrast to the species-specific response in infected animals, sera from animals vaccinated with inactivated human cell-grown SIV reacted to both human and rhesus MHC class I and class II molecules.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.18989-0
2003-07-01
2020-09-30
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/7/vir841671.html?itemId=/content/journal/jgv/10.1099/vir.0.18989-0&mimeType=html&fmt=ahah

References

  1. Arthur L. O., Bess J. W. Jr, Sowder R. C. II, Benveniste R. E., Mann D. L., Chermann J. C., Henderson L. E.. 1992; Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science258:1935–1938
    [Google Scholar]
  2. Arthur L. O., Bess J. W. Jr, Urban R. G., Strominger J. L., Morton W. L., Mann D. L., Henderson L. E., Benveniste R. E.. 1995; Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J Virol69:3117–3124
    [Google Scholar]
  3. Benkirane M., Blanc-Zouaoui D., Hirn M., Devaux C.. 1994; Involvement of human leukocyte antigen class I molecules in human immunodeficiency virus infection of CD4-positive cells. J Virol68:6332–6339
    [Google Scholar]
  4. Bergmeier L. A., Walker J., Tao L., Cranage M., Lehner T.. 1994; Antibodies to human and non-human primate cellular and culture medium components in macaques vaccinated with the simian immunodeficiency virus. Immunology83:213–220
    [Google Scholar]
  5. Cantin R., Fortin J.-F., Lamontagne G., Tremblay M.. 1997; The presence of host-derived HLA-DR1 on human immunodeficiency virus type 1 increases viral infectivity. J Virol71:1922–1930
    [Google Scholar]
  6. Cantin R., Martin G., Tremblay M. J.. 2001; A novel virus capture assay reveals a differential acquisition of host HLA-DR by clinical isolates of human immunodeficiency virus type 1 expanded in primary human cells depending on the nature of producing cells and the donor source. J Gen Virol82:2979–2987
    [Google Scholar]
  7. Chan W. L., Rodgers A., Hancock R. D., Taffs F., Kitchin P., Farrar G., Liew F. Y.. 1992; Protection of simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response. J Exp Med176:1203–1207
    [Google Scholar]
  8. Chan W. L., Rodgers A., Grief C.. 8 other authors 1995; Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac-32H. AIDS9:223–228
    [Google Scholar]
  9. Cranage M. P., Baskerville A., Ashworth L. A. E.. & 7 other authors (1992a). Intrarectal challenge of macaques vaccinated with formalin-inactivated simian immunodeficiency virus. Lancet339:273–274
    [Google Scholar]
  10. Cranage M. P., Ashworth L. A. E., Greenaway P. J., Murphey-Corb M., Desrosiers R. C.. 1992b; AIDS vaccine developments. Nature355:685–686
    [Google Scholar]
  11. Cranage M. P., Polyanskaya N., McBride B.. 12 other authors 1993; Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Hum Retrovir9:13–22
    [Google Scholar]
  12. Daniel V., Schimpf K., Opelz G.. 1989; Lymphocyte autoantibodies and alloantibodies in HIV-positive haemophilia patients. Clin Exp Immunol75:178–183
    [Google Scholar]
  13. De La Barrera S., Fainboim L., Lugo S., Picchio G. R., Muchnik G. R., De Bracco M. M. E.. 1987; Anti-class II antibodies in AIDS patients and AIDS-risk groups. Immunology62:599–604
    [Google Scholar]
  14. De Santis C., Robbioni P., Longhi R., Lopalco L., Siccardi A. G., Beretta A., Roberts N. J. Jr. 1993; Cross-reactive response to human immunodeficiency virus type 1 (HIV-1) gp120 and HLA class I heavy chains induced by receipt of HIV-1-derived envelope vaccines. J Infect Dis168:1396–1403
    [Google Scholar]
  15. De Santis C., Lapalco L., Robbioni P., Longhi R., Rappocciolo G., Siccardi A. G., Beretta A.. 1994; Human antibodies to immunodominant C5 region of HIV-1 gp120 cross-react with HLA class I on activated cells. AIDS Res Hum Retrovir10:157–162
    [Google Scholar]
  16. Dorsett B., Cronin W., Chuma V., Iochim H. L.. 1985; Anti-lymphocyte antibodies in patients with the acquired immune deficiency syndrome. Am J Med78:621–626
    [Google Scholar]
  17. Fortin J.-F., Cantin R., Lamontagne G., Tremblay M.. 1997; Host-derived ICAM-1 glycoproteins incorporated on human immunodeficiency virus type 1 are biologically active and enhance viral infectivity. J Virol71:3588–3596
    [Google Scholar]
  18. Golding H., Shearer G. M., Hillman K.. 7 other authors 1989; Common epitope in human immunodeficiency virus (HIV) 1-gp41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV 1-infected individuals. J Clin Invest83:1430–1435
    [Google Scholar]
  19. Grassi F., Menervi R., Gullberg M.. 9 other authors 1991; Human immunodeficiency virus type 1 gp120 mimics a hidden monomorphic epitope borne by class I major histocompatibility complex heavy chains. J Exp Med174:53–62
    [Google Scholar]
  20. Habeshaw J. A.. 1994; HLA mimicry by HIV-1 gp120 in the pathogenesis of AIDS. Immunol Today15:39–40
    [Google Scholar]
  21. Henderson L. E., Sowder R., Copeland T. D., Oroszlan S., Arthur L. O., Robey W. G., Fischinger P. J.. 1987; Direct identification of class II histo-compatibility Dr proteins in preparations of human T-cell lymphotropic virus type III. J Virol61:629–632
    [Google Scholar]
  22. Hoxie J. A., Fitzharris T. P., Youngbar P. R., Mathews S. D. M., Rackowski J. L., Radka S. F.. 1987; Non-random association of cellular antigens with HTLV-III virions. Hum Immunol18:39–52
    [Google Scholar]
  23. Kion T. A., Hoffmann G. W.. 1991; Anti-HIV and anti-MHC antibodies in alloimmune and autoimmune mice. Science253:1138–1140
    [Google Scholar]
  24. Langlois A. J., Weinhold K. J., Mathews T. J., Greenberg M. L., Bolognesi D. P.. 1992; Detection of anti-human cell antibodies in sera from macaques immunized with whole inactivated virus. AIDS Res Hum Retrovir8:1641–1652
    [Google Scholar]
  25. Meier T., Arni S., Malarkannan S., Poincelet M., Hoessli D.. 1992; Immunodetection of biotinylated lymphocyte-surface proteins by enhanced chemiluminescence: a nonradioactive method for cell-surface protein analysis. Anal Biochem204:220–226
    [Google Scholar]
  26. Müller C., Kukel S., Schneweis K. E., Bauer R.. 1994; Anti-lymphocyte antibodies in plasma of HIV-1-infected patients preferentially react with MHC class II-negative T cells and are linked to antibodies against gp41. Clin Exp Immunol97:367–372
    [Google Scholar]
  27. Nguyen D. H., Hildreth J. E.. 2000; Evidence for budding of human immunodeficiency virus type 1 selectively from glycolipid-enriched membrane lipid rafts. J Virol74:3264–3272
    [Google Scholar]
  28. Ozturk G. E., Kohler P. F., Horsburgh C. R. Jr, Kirkpatrick C. H.. 1987; The significance of anti-lymphocyte antibodies in patients with acquired immune deficiency syndrome (AIDS) and their sexual partners. J Clin Immunol7:130–139
    [Google Scholar]
  29. Polyanskaya N., Sharpe S., Cook N., Leech S., Banks J., Dennis M., Hall G., Stott J., Cranage M.. 1997; Anti-major histocompatibility complex antibody responses to simian B cells do not protect macaques against SIVmac infection. AIDS Res Hum Retrovir13:923–931
    [Google Scholar]
  30. Poon D. T., Coren L. V., Ott D. E.. 2000; Efficient incorporation of HLA class II onto human immunodeficiency virus type 1 requires envelope glycoprotein packaging. J Virol74:3918–3923
    [Google Scholar]
  31. Riera N. E., Galassi N., de la Berrera S., Rickard E., Muchinik G., Perez-Bianco R., de Bracco M. M. E.. 1992; Anti-leukocyte antibodies as a consequence of HIV infection in HIV+ individuals. Immunol Lett33:99–104
    [Google Scholar]
  32. Rossio J. L., Bess J. Jr, Henderson L. E., Cresswell P., Arthur L. O.. 1995; HLA class II on HIV particles is functional in superantigen presentation to human T cells: implications for HIV pathogenesis. AIDS Res Hum Retrovir11:1433–1439
    [Google Scholar]
  33. Saifuddin M., Ghassemi M., Patki C., Parker C. J., Spear G. T.. 1994; Host cell components affect the sensitivity of HIV type 1 to complement-mediated virolysis. AIDS Res Hum Retrovir10:829–837
    [Google Scholar]
  34. Saifuddin M., Parker C. J., Peebles M. E., Gorny M. K., Zolla-Pazner S., Ghassemi M., Rooney I. A., Atkinson J. P., Spear G. T.. 1995; Role of virion-associated glycosylphosphatidylinositol-linked proteins CD55 and CD59 in complement resistance of cell line-derived and primary isolates of HIV-1. J Exp Med182:501–509
    [Google Scholar]
  35. Spear G. T., Olinger G. G., Saifuddin M., Gebel H. M.. 2001; Human antibodies to major histocompatibility complex alloantigens mediate lysis and neutralization of HIV-1 primary isolate virions in the presence of complement. J Acquir Immune Defic Syndr26:103–110
    [Google Scholar]
  36. Stott E. J.. 1991; Anti-cell antibody in macaques. Nature353:393
    [Google Scholar]
  37. Stott E. J., Almond N., West W., Kent K., Cranage M. P., Rud E.. 1994; Protection against simian immunodeficiency virus infection of macaques by cellular or viral antigens. Neuviéme Colloque des Cent Gardes 219–224
    [Google Scholar]
  38. Tremblay M. J., Fortin J.-F., Cantin R.. 1998; The acquisition of host-encoded proteins by nascent HIV-1. Immunol Today19:346–351
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.18989-0
Loading
/content/journal/jgv/10.1099/vir.0.18989-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error